According to a recent NIH-funded analysis, applying the clinical trial eligibility criteria for monoclonal antibodies resulted in only a small fraction of participants with Alzheimer's disease being eligible to receive treatment. The ANAVEX 2-73-AD-004 Alzheimer's disease placebo-controlled Phase 2b/3 trial showed that in addition to significant improvement in dementia symptoms, blarcamesine demonstrated reduction of pathological aggregation of amyloid in early Alzheimer's disease as well reduction of brain volume loss, a well-known marker of neurodegeneration. Data from the blarcamesine in Alzheimer's disease Phase 2b/3 randomized, placebo-controlled clinical trial will be published in an upcoming peer-reviewed journal.